Literature DB >> 32516136

Minor snRNA gene delivery improves the loss of proprioceptive synapses on SMA motor neurons.

Erkan Y Osman1, Meaghan Van Alstyne2, Pei-Fen Yen1, Francesco Lotti2, Zhihua Feng3, Karen Ky Ling3, Chien-Ping Ko3, Livio Pellizzoni2, Christian L Lorson1.   

Abstract

Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder caused by reduced expression of the survival motor neuron (SMN) protein. SMN has key functions in multiple RNA pathways, including the biogenesis of small nuclear ribonucleoproteins that are essential components of both major (U2-dependent) and minor (U12-dependent) spliceosomes. Here we investigated the specific contribution of U12 splicing dysfunction to SMA pathology through selective restoration of this RNA pathway in mouse models of varying phenotypic severity. We show that virus-mediated delivery of minor snRNA genes specifically improves select U12 splicing defects induced by SMN deficiency in cultured mammalian cells, as well as in the spinal cord and dorsal root ganglia of SMA mice without increasing SMN expression. This approach resulted in a moderate amelioration of several parameters of the disease phenotype in SMA mice, including survival, weight gain, and motor function. Importantly, minor snRNA gene delivery improved aberrant splicing of the U12 intron-containing gene Stasimon and rescued the severe loss of proprioceptive sensory synapses on SMA motor neurons, which are early signatures of motor circuit dysfunction in mouse models. Taken together, these findings establish the direct contribution of U12 splicing dysfunction to synaptic deafferentation and motor circuit pathology in SMA.

Entities:  

Keywords:  Neurodegeneration; Neuroscience

Mesh:

Substances:

Year:  2020        PMID: 32516136      PMCID: PMC7406293          DOI: 10.1172/jci.insight.130574

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  81 in total

1.  A critical smn threshold in mice dictates onset of an intermediate spinal muscular atrophy phenotype associated with a distinct neuromuscular junction pathology.

Authors:  Mélissa Bowerman; Lyndsay M Murray; Ariane Beauvais; Bruno Pinheiro; Rashmi Kothary
Journal:  Neuromuscul Disord       Date:  2011-11-08       Impact factor: 4.296

2.  Interaction of proteins with promoter elements of the human U2 snRNA genes in vivo.

Authors:  Diana C Boyd; Ana Pombo; Shona Murphy
Journal:  Gene       Date:  2003-10-02       Impact factor: 3.688

Review 3.  Disease mechanisms and therapeutic approaches in spinal muscular atrophy.

Authors:  Sarah Tisdale; Livio Pellizzoni
Journal:  J Neurosci       Date:  2015-06-10       Impact factor: 6.167

Review 4.  A role for the survival of motor neuron protein in mRNP assembly and transport.

Authors:  Paul G Donlin-Asp; Gary J Bassell; Wilfried Rossoll
Journal:  Curr Opin Neurobiol       Date:  2016-04-29       Impact factor: 6.627

5.  Bifunctional RNAs targeting the intronic splicing silencer N1 increase SMN levels and reduce disease severity in an animal model of spinal muscular atrophy.

Authors:  Erkan Y Osman; Pei-Fen Yen; Christian L Lorson
Journal:  Mol Ther       Date:  2011-10-25       Impact factor: 11.454

6.  SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN.

Authors:  Thanh T Le; Lan T Pham; Matthew E R Butchbach; Honglai L Zhang; Umrao R Monani; Daniel D Coovert; Tatiana O Gavrilina; Lei Xing; Gary J Bassell; Arthur H M Burghes
Journal:  Hum Mol Genet       Date:  2005-02-09       Impact factor: 6.150

Review 7.  Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease?

Authors:  Monir Shababi; Christian L Lorson; Sabine S Rudnik-Schöneborn
Journal:  J Anat       Date:  2013-07-22       Impact factor: 2.610

8.  Spliceosome integrity is defective in the motor neuron diseases ALS and SMA.

Authors:  Hitomi Tsuiji; Yohei Iguchi; Asako Furuya; Ayane Kataoka; Hiroyuki Hatsuta; Naoki Atsuta; Fumiaki Tanaka; Yoshio Hashizume; Hiroyasu Akatsu; Shigeo Murayama; Gen Sobue; Koji Yamanaka
Journal:  EMBO Mol Med       Date:  2013-01-25       Impact factor: 12.137

9.  Dysregulation of Mdm2 and Mdm4 alternative splicing underlies motor neuron death in spinal muscular atrophy.

Authors:  Meaghan Van Alstyne; Christian M Simon; S Pablo Sardi; Lamya S Shihabuddin; George Z Mentis; Livio Pellizzoni
Journal:  Genes Dev       Date:  2018-07-16       Impact factor: 11.361

10.  SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing.

Authors:  Zhenxi Zhang; Francesco Lotti; Kimberly Dittmar; Ihab Younis; Lili Wan; Mumtaz Kasim; Gideon Dreyfuss
Journal:  Cell       Date:  2008-05-16       Impact factor: 41.582

View more
  5 in total

Review 1.  Regulation of ER-derived membrane dynamics by the DedA domain-containing proteins VMP1 and TMEM41B.

Authors:  Yutaro Hama; Hideaki Morishita; Noboru Mizushima
Journal:  EMBO Rep       Date:  2022-01-19       Impact factor: 8.807

Review 2.  History of development of the life-saving drug "Nusinersen" in spinal muscular atrophy.

Authors:  Jiaying Qiu; Liucheng Wu; Ruobing Qu; Tao Jiang; Jialin Bai; Lei Sheng; Pengchao Feng; Junjie Sun
Journal:  Front Cell Neurosci       Date:  2022-08-12       Impact factor: 6.147

3.  Neuromuscular denervation and deafferentation but not motor neuron death are disease features in the Smn2B/- mouse model of SMA.

Authors:  Maria J Carlini; Marina K Triplett; Livio Pellizzoni
Journal:  PLoS One       Date:  2022-08-01       Impact factor: 3.752

4.  SMN controls neuromuscular junction integrity through U7 snRNP.

Authors:  Sarah Tisdale; Meaghan Van Alstyne; Christian M Simon; George Z Mentis; Livio Pellizzoni
Journal:  Cell Rep       Date:  2022-09-20       Impact factor: 9.995

Review 5.  Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine.

Authors:  Helena Chaytow; Kiterie M E Faller; Yu-Ting Huang; Thomas H Gillingwater
Journal:  Cell Rep Med       Date:  2021-07-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.